• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Fluorescent imaging agent goes to market

Article

Fluorescent imaging agent goes to marketVPDiagnostics mints MR plaque analysis softwareZiosoft unveils subscription program

Fluorescent imaging agent goes to market

VisEn Medical, a specialist in fluorescence in vivo imaging, launched a new in vivo imaging agent for preclinical research. Following the launch of IntegriSense 680, the new agent, IntegriSense 750, is tuned to the assessment of integrin αvβ3, a biomarker closely associated with disease-related vascularity and angiogenesis. The agent was developed out of the Merck-VisEn Biomarker Imaging research collaboration to enable in vivo imaging of the biomarker's expression in order to measure and monitor aspects of disease progression and therapeutic response of disease states including oncology, cardiovascular disease, and bone disease.

VPDiagnostics mints MR plaque analysis software

Postprocessing software firm VPDiagnostics has developed a way to document carotid artery atherosclerosis MR angiograms. The tool, MRI-PlaqueView, is set to begin a multicenter clinical trial sponsored by the NIH. Cleared in December 2008, the software provides semiautomated tools, a streamlined workflow, and an optimized user interface.

Ziosoft unveils subscription program

The imaging community need not dip into its capital equipment budget for thin-client postprocessing from Ziosoft. The Japanese company has launched a monthly subscription program that allows customers to gain access to its 3D advanced visualization system, which reconstructs large image data sets acquired from CT and MR systems.

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.